Arcturus Therapeutics
ARCT
144 hedge funds and large institutions have $678M invested in Arcturus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 41 increasing their positions, 52 reducing their positions, and 11 closing their positions.
191% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 11
22% more capital invested
Capital invested by funds: $558M → $678M (+$120M)
16% more funds holding
Funds holding: 124 → 144 (+20)
1.18% more ownership
Funds ownership: 87.8% → 88.98% (+1.2%)
21% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 52
45% less call options, than puts
Call options by funds: $4.75M | Put options by funds: $8.67M
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$7.23M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$6.84M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.67M |
| 4 |
BlackRock
New York
|
+$5.33M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.44M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$20.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.91M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$6.11M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.25M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.58M |
ARCT Hedge Fund Activity: Q2 2023 in Review
144 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2023, worth a combined $678M — up 22% from $558M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ARCT positions and 11 closed out — a net gain of 21 holders — while 41 added to existing stakes and 52 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $7.23M. The largest seller was Bank of America, cutting an estimated $20.8M.
- 144 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2023, up from 124 in Q1 2023.
- Funds reported $678M of Arcturus Therapeutics stock for Q2 2023, up 22% quarter-over-quarter.
- 32 funds opened new Arcturus Therapeutics positions in Q2 2023 and 11 closed out, a net change of +21 holders.
- The largest Arcturus Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $7.23M added.
- The largest Arcturus Therapeutics seller in Q2 2023 was Bank of America, an estimated $20.8M sold.
Based on aggregated 13F filings for Q2 2023.